linjc16/ctgov huggingface dataset:
MRI as Alternative to CBCT for the Assessment of Furcation Involvement in Molars

Study Overview
=================
Brief Summary
-----------------
Aim of this prospective study is to compare magnetic resonance imaging (MRI) and cone beam computed tomography (CBCT) to diagnose furcation involvement (FI) in molars in patients with periodontitis. The focus is on the differentiation of grad II and III according to Hamp et al. 1975. 140 molars (70 upper and 70 lower) will be investigated with CBCT and MRI. Due to the absence of ionic radiation MRI might be a radiation free diagnostic tool to assess FI in the future without harmful radiation for the patient. Patients of the Dental Clinic, Medical University of Vienna, who need a CBCT and have a clinically diagnosed FI can be a participant of this clinical trial and do in addition to their CBCT a MRI. The accuracy of MRI will be compared to the diagnostic gold standard CBCT. If patients need additional periodontal treatment, e.g., periodontal surgery, a subgroup will also be analysed with intraoperative measurements.

Official Title
-----------------
Evaluation of Magnetic Resonance Imaging as Alternative to Cone Beam Computed Tomography for the Assessment of Furcation Involvement in Molars

Conditions
-----------------
Periodontitis, Periodontal Diseases, Furcation Defects

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with FI grade II or III, patients who need a CBCT, not pregnant Exclusion Criteria: Patients with contraindications to perform a MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| horizontal furcation defects according to Hamp 1975 | Grad 0, I, II, III | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| horizontal bone loss | measured in mm | day 1 | 
| vertical bone loss | measured in mm | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI, CBCT, Furcation involvement
Effectiveness and Safety of Distal Left Transradial Access in Coronary Procedures.

Study Overview
=================
Brief Summary
-----------------
To evaluate the effectiveness and safety of distal left radial (dLR) access in coronary procedures at a tertiary center in Trinidad and Tobago.

Detailed Description
-----------------
An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.

Official Title
-----------------
Effectiveness and Safety of Distal Left Transradial Access in Coronary Procedures.

Conditions
-----------------
Cardiovascular Diseases, Cardiomyopathies

Intervention / Treatment
-----------------
* Procedure: cardiac catheterization


Participation Criteria
=================
Eligibility Criteria
-----------------
Cardiologist recommended guidelines.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiologist Assessed Conditions.<br>The consultant Cardiologist will decide on the various types of presentations and symptoms that will be use full in generating this study. | Procedure: cardiac catheterization<br>* An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of snuff box access to radial access for coronary angiography in Trinidad and Tobago. | An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box. | roughly 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Distal Radial Artery Angiogram, Anatomical Snuff Box Angiogram
P200TE US Reference Database Study

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to collect Optical Coherence Tomography (OCT) data to construct a reference database for the P200TE.

Detailed Description
-----------------
The objective of this study is to collect Optical Coherence Tomography (OCT) data on healthy eyes in order to develop a reference database for the P200TE device in order to determine the reference limits for the P200TE

Official Title
-----------------
Optos P200TE US Reference Database Study

Conditions
-----------------
Normal Eyes

Intervention / Treatment
-----------------
* Device: P200TE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 22 years of age or older on the date of informed consent Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent Subjects presenting at the site with normal eyes (Cataracts, LASIK, PRK (photorefractive keratectomy), and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed. BCVA (best corrected visual acuity) 20/40 or better(each eye) Subject is able to comply with the study procedures Exclusion Criteria: Subjects unable to tolerate ophthalmic imaging Subject has a condition or is in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study Subject with ocular media not sufficiently clear toobtain acceptable OCT images .History of leukemia, dementia or multiple sclerosis

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: OCT<br>Device: P200TE The P200TE provides OCT imaging including retina topography and ONH (optic nerve head) scans. | Device: P200TE<br>* The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal Thickness | The full thickness retina grid consists of a 9-sector circular grid pattern centered on the fovea and based on the ETDRS criteria. | 1 year | 
| GCC Thickness | The GCC Thickness | 1 year | 
| RNFL Thickness | The RNFL thickness | 1 year | 
| Optic Nerve Head | The ONH size | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events | Number of any adverse events associated with the clinical study to ensure device safety. | 1 year |
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

Study Overview
=================
Brief Summary
-----------------
This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

Detailed Description
-----------------
This study includes three stages: screening period, treatment period and safety follow-up period.

Official Title
-----------------
A Single-arm Study Sponsored by Investigators to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Recurrent IgG4-related Diseases

Conditions
-----------------
IgG4 Related Disease

Intervention / Treatment
-----------------
* Biological: CM310


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18 years, male and female. With IGG4-related disease. Exclusion Criteria: Inoculate live vaccine within 4 weeks before screening. Treponema pallidum antibody positive in screening period. Active hepatitis in screening period. With a history of solid organ or cell transplantation within 6 months before screening. With other medical or non-medical conditions that are not suitable for the study by the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CM310<br>CM310, subcutaneous | Biological: CM310<br>* CM310 Injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate | Response rate after administration for 12 weeks | up to week 12 |
Prevention of Shivering Associated With Spinal Anesthesia

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare the effectiveness of prophylactic use of intravenous (IV) dexmedetomidine VS ketamine and meperidine(as a control group) in prevention of shivering associated with intrathecal anesthesia in patients undergoing knee arthroscopy

Official Title
-----------------
Dexmedetomidine Versus Ketamine to Prevent Shivering Associated With Intrathecal Anesthesia in Patients Undergoing Knee Arthroscopy:A Randomized, Controlled Double Blinded Study.

Conditions
-----------------
Shivering, Spinal Anesthesia

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine
* Drug: Ketamine
* Drug: Meperidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - BMI 20-30 Scheduled patients for knee arthroscopy under spinal anesthesia. American Society of Anesthesiologists (ASA) physical status: I and II Exclusion Criteria: Patient refusal Aged less than 18 years or lesser than 150 cm in height Pregnant woman Allergy to the studied drugs. Patients with contraindications to spinal anesthesia. Patients with advanced decompensated cardiac, respiratory,renal or hepatic diseases, ASA III-IV Coagulopathy or thrombocytopenia CNS diseases as epilepsy, stroke or psychiatric illness.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group D (dexmedetomidine group)<br> | Drug: Dexmedetomidine<br>* Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia<br>|
| Active Comparator: Group K (ketamine group)<br> | Drug: Ketamine<br>* Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia<br>|
| Placebo Comparator: Group C (control group)<br> | Drug: Meperidine<br>* If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of shivering | Incidence of shivering post intrathecal anesthesia is recorded | During operation time |
Posterior Circulation ASTRAL Prognostic Score

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to develop a prognostic score for ischemic posterior circulation strokes, based on our previous work on with the ASTRAL scores (Acute STroke Registry and Analysis of Lausanne) on overall stroke prognosis, intracranial occlusion, recanalization and stroke recurrences. The main question it aims to answer is the modified Rankin score in 3 months after the event. Participants will be patients with acute ischemic stroke of the posterior circulation with mRS priot to event <3. All the data will be collected retrospectively from patients included in the ASTRAL registry between January 2003 and December 2021. The ASTRAL registry will be used as the derivation cohort of the score. Demographics, acute glucose, NIHSS score and acute imaging of each participant will be used from the derivation cohort in order to create an integer-based prognostic score. After internal validation, we plan to validate the score in external stroke registries to show its validity.

Official Title
-----------------
Pc-ASTRAL Score for the Prediction of 3 Months Functional Outcome in Acute Ischemic Stroke at the Posterior Circulation

Conditions
-----------------
Stroke Ischemic, Stroke Acute, Posterior Circulation Brain Infarction

Intervention / Treatment
-----------------
* Diagnostic Test: ASTRAL prognostic score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Isolated posterior circulation strokes based on clinical or/and imaging evidence. Arriving within 24h at hospital since last proof of good health. Exclusion Criteria: no available data for 3 months modified Rankin Score modified Rankin Score≥3 prior the event
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ASTRAL<br> | Diagnostic Test: ASTRAL prognostic score<br>* ASTRAL prognostic score<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3 months modified Ranking scale | evaluation of 3 months neurological disability | January 2003-December 2021 |
Relinking Diagnosed But Untreated HCV Patients Back Into Care.

Study Overview
=================
Brief Summary
-----------------
Reintroduction of patients into a HCV infection care pathway after a positive chronic hepatitis C diagnosis by previous testing in our hospital who were lost in follow-up. Gaining insight in the possible reasons why patients are lost in follow-up after positive hepatitis C serology.

Official Title
-----------------
Relinking Diagnosed But Untreated HCV Patients Back Into Care.

Conditions
-----------------
Hepatitis C Virus Infection

Intervention / Treatment
-----------------
* Other: Contact the patient


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive HCV serology between 2012-2022 with positive or uknown HCV RNA in UZ Brussels database ≥18 years Exclusion Criteria: Positive HCV serology with negative HCV RNA Previously eradicated patients in UZ Brussel

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diagnosed-but-untreated<br>Diagnosed but untreated (DBU) HCV patients through positive serology with positive or unknown HCV RNA in UZ Brussel between 2012 - 2022. | Other: Contact the patient<br>* Phone call, email or letter to contact the patient to relink them.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective data collection | Prevalence of diagnosed but untreated HCV patients through positive serology with positive or unknown HCV RNA in UZ Brussel between 2012 - 2022. | before contacting the patient | 
| Prospective interventional study | To recall DBU patients by phone, e-mail or letter, trying to optimize treated and cured patients after recall | from first contact of the patient till 12 weeks after end of treatment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reason lost in follow-up | Understanding the different reasons why patients were lost in follow-up with the aim of improving our hospital quality in the future: Unaware of positive hep C serology Follow-up or treatment in other centre Refusal of previously proposed therapy Other? | from first contact of the patient till 12 weeks after end of treatment. |
Evaluate the Relevance of the Use of Peripheral Venous Blood Gases for the Care of Patients in the S.A.U.V (Vital Emergency Rooms) of the CHU de Caen

Study Overview
=================
Brief Summary
-----------------
concordance between the lactate values on peripheral venous and arterial blood gases in all patients receiving an arterial sample on their arrival in the S.A.U.V.

Official Title
-----------------
Evaluate the Relevance of the Use of Peripheral Venous Blood Gases for the Care of Patients in the S.A.U.V (Vital Emergency Rooms) of the CHU de Caen

Conditions
-----------------
Critical Illness

Intervention / Treatment
-----------------
* Other: peripheral venous blood gases


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: one of this condition in emergency unit : acute respiratory distress a suspicion of an acid-base disorder a state of shock Pathologies requiring monitoring of the respiratory system Patient under NIV Poisoning Coma with a Glasgow score < or equal to 8 Exclusion Criteria: Patient presenting another pathology supported in SAUV not requiring the realization of arterial blood gases Patient aged < 18 years Pregnant or breastfeeding woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Peripheral Venous Blood Gases<br> | Other: peripheral venous blood gases<br>* peripheral venous blood gases<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lactates on peripheral venous and arterial blood gases | mmol/L | baseline |
The Effect of Alginate Encapsulated Supplements on Athletic Performance and Recovery

Study Overview
=================
Brief Summary
-----------------
Endurance sport is often characterized by high training loads and significant metabolic demands, including depletion of endogenous fuel stores (e.g. liver and muscle glycogen) and damage to the skeletal muscle proteins. Nutritional interventions that enhance the restoration of endogenous fuel stores and improve muscle damage repair have received a lot of attention. The primary aim of this project is to clinically test the effect of alginate encapsulation technology on performance. Furthermore, we will investigate the substrate utilization profile during exercise and subsequent recovery. The encapsulation technology presents a nutrient delivery solution, which results in a sustained or slow-release of the nutrients encapsulated. Thus, potentially optimizing the digestion and absorption by promoting an easy ingestion of high concentrations of fx carbohydrates without negatively affecting the gastrointestinal comfort.

Official Title
-----------------
The Effect of Alginate Encapsulated Supplements on Athletic Performance and Recovery

Conditions
-----------------
Athletic Performance

Intervention / Treatment
-----------------
* Dietary Supplement: Slow-release CHO-AA
* Dietary Supplement: Slow-release CHO
* Dietary Supplement: CHO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males between 18-50 years of age moderate to trained individuals with a VO2max > 50 ml/min/kg accustumed to exercising on a bike healthy volunteers Exclusion Criteria: persons diagnosed with metabolic diseases (i.e. Type 2 Diabetes) which relates to the carbohydrate metabolism. persons ingesting prescribed drugs/medicin, supplements or a special diet (i.e. low carbohydrate), which might affect the glycogen synthesis and/or performance.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Slow-release CHO-AA<br>Alginate encapsulated Carbohydrates and Amino Acids | Dietary Supplement: Slow-release CHO-AA<br>* Slow-release CHO-AA, alginate encapsulated<br>|
| Experimental: Slow-release CHO<br>Alginate encapsulated Carbohydrates | Dietary Supplement: Slow-release CHO<br>* Slow-release CHO, alginate encapsulated<br>|
| Active Comparator: CHO<br>Carbohydrates only | Dietary Supplement: CHO<br>* Carbohydrate-only, control<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance | Time-To-Exhaustion performance test | approx. 90 min-120 min |